PIK3CA mutations and BRCA1 expression in breast cancer: Potential biomarkers for chemoresistance

Cancer Investigation

Volumn 26, Issue 10, 2008, Pages 1044-1051

  Santarpia, Mariacarmela ^a,b   Altavilla, Giuseppe ^a   Margeli, Mireia ^b   Cirauqui, Beatriz ^b   Mesiti, Mario ^a   Cavallari, Vittorio ^a   Ramirez, Jose Luis ^b   Sanchez Ronco, Maria ^c   Santarpia, Libero ^d   Taron, Miquel ^b   Rosell, Rafael ^b,e  

^a UNIVERSITY OF MESSINA   (Italy)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Medical Oncology Service

Author keywords

BRCA1 expression; Breast cancer; Chemoresistance; PIK3CA mutations

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CODON; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MUTATION; NEOPLASM STAGING; RECEPTOR, ERBB-2; RNA, MESSENGER; RNA, NEOPLASM; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 57749201846     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802112701     Document Type: Article

References (29)

1. Vanhaesebroeck, B.; Waterfield, M.D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999, 253, 239-254.
2. Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96, 857-868.
3. Aoki, M.; Blazek, E.; Vogt, P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 2001, 98, 136-141.
4. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S.M.; Riggins, G.J.; Willson, J.K.; Markowitz, S.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304, 554.
5. Schonleben, F.; Ciau, N.T.; Ho, D.J. ; Li, X.; Allendorf, J.D.; Remotti, H.E.; Su, G.H. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006, 12, 3851-3855.
6. Lee, J.W.; Soung, Y.H.; Kim, S.Y.; Lee, H. W.; Park, W.S.; Nam, S.W.; Kim, S.H.; Lee, J.Y.; Yoo, N.J.; Lee, S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24, 1477-1480.
7. Levine, D.A.; Bogomolniy, F.; Yee, C.J.; Lash, A.; Barakat, R.R.; Borgen, P.I.; Boyd, J. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005, 11, 2875-2878.
8. Wang, Y.; Helland, A.; Holm, R.; Kristensen, G.B.; Borresen-Dale, A-L. PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005, 25(3), 322.
9. Oda, K.; Stokoe, D.; Taketani, Y.; McCormick, F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005, 65(23), 10669-10673.
10. Garcia-Rostan, G.; Costa, A. M.; Pereira-Castro, I.; Salvatore, G.; Hernandez, R.; Hermsem, M.J.; Herrero, A.; Fusco, A.; Cameselle-Teijeiro, J.; Santoro, M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005, 65, 10199-10207.
11. López-Knowles, E.; Hernández, S.; Malats, N.; Kogevinas, M.; Lloreta, J.; Carrato, A.; Tardón, A.; Serra, C.; Real, F.X. and EPICURO Study Group Investigators. PIK3CA Mutations Are an Early Genetic Alterations Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors. Cancer Res 2006, 66, 7401-7404.
12. Kawano, O.; Sasaki, H.; Endo, K.; Suzuki, E.; Haneda, H.; Yukiue, H.; Kobayashi, Y.; Yano, M.; Fujii, Y. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006, 54(2), 209-215.
13. Kang, S.; Bader, A.G.; Vogt, P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005, 102(3), 802-807.
14. Samuels, Y.; Diaz Jr., L.; Schmidt-Kittler, O.; Cummins, J.M. ; DeLong, L.; Cheong, I. ; Rago, C.; Huso, D.L.; Lengauer, C.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7, 561-573.
15. Guo, X.N.; Rajput, A.; Rose, R.; Hauser, J.; Beko, A.; Kuropatwinski, K.; LeVea, C.; Hoffman, R.M.; Brattain, M.G.; Wang, J. Mutant PIK3CA-bearing colon cancer cell display increased metastasis in an orthotopic model. Cancer Res 2007, 67, 5851-5858.
16. Bachman, K.E.; Argani, P.; Samuels, Y.; Silliman, N.; Ptak, J.; Szabo, S.; Konishi, H.; Karakas, B.; Blair, B.G.; Lin, C.; Peters, B.A.; Velculescu, V.E.; Park, B.K. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004, 3, 772-775.
17. Wu, G.; Xing, M.; Mambo, E.; Huang, X.; Liu, J.; Guo, Z.; Chatterjee, A.; Goldenberg, D.; Gollin, S.M.; Sukumar, S.; Trink, B.; Sidransky, D. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005, 7(5), 609-616.
18. Campbell, I.G.; Russell, S.E.; Choong, D.Y.; Montgomery, K.G.; Ciavarella, M.L.; Hooi, C.S.; Cristiano, B.E.; Pearson, R.B.; Phillips, W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64(21), 7678-7681.
19. Reed, E.; Yu, J.J.; Davies, A.; Gannon, J.; Armentrout, S.L. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 2003, 9, 5299-5305.
20. Quinn, J.E.; Kennedy, R.D.; Mullan, P.B.; Gilmore, P.M. ; Carty, M.; Johnston, P.G.; Harkin, D.P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63, 6221-6228.
21. Tassone, P.; Tagliaferri, P.; Perricelli, A.; Blotta, S.; Quaresima, B.; Martelli, M.L.; Goel, A.; Barbieri, V.; Costanzo, F.; Boland, C.R.; Venuta, S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003, 88, 1285-1291.
22. Saal, L.H.; Holm, K.; Maurer, M.; Memeo, L.; Su, T.; Wang, X.; Yu, J.S.; Malmstrom, P.O.; Mansukhani, M.; Enoksson, J.; Hibshoosh, H.; Borg, A.; Parsons, R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65(7), 2554-2559.
23. Pérez-Tenorio, G.; Alkhori, L.; Olsson, B.; Waltersson, M.A.; Nordenskjsöld, B.; Rutqvist, L.E.; Skoog, L.; Stal, O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007, 13, 3577-3584.
24. Maruyama, N.; Miyoshi, Y.; Taguchi, T.; Tamaki, Y.; Monden, M.; Noguchi, S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007, 13, 408-414.
25. Li, S.Y.; Rong, M.; Grieu, F.; Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006, 96(1), 91-95.
26. Quinn, J.E.; James, C.R.; Stewart, G.E.; Mulligan, J.M.; White, P.; Chang, K.F.; Mullan, P.B.; Johnston, P.G.; Wilson R.H.; Harkin D.P. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007, 13(24), 7413-7420.
27. Taron, M.; Rosell, R.; Felip, E.; Mendez, P.; Souglakos, J.; Sanchez-Ronco, M.; Queralt, C.; Majo, J.; Sanchez, J.M.; Sanchez, J.J.; Maestre, J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics 2004, 13(20), 2443-2449.
28. Hayes, D.F.; Thor, A.D.; Dressler, L.G.; Weaver, D.; Edgerton, S.; Cowan, D.; Broadwater, G.; Goldstein, L.J.; Martino, S; Ingle, J.N.; Henderson, C.; Norton, L.; Winer, E.P.; Hudis, C.A.; Ellis, M.J.; Berry, D.A.; for the Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357, 1496-1506.
29. Zhang, L.; Yang, N.; Liang, S.; Barchetti, A,; Vezzani, C.; Huang, J.; O'Brien-Jenkins, A.; Rubin, S.C.; Coukos, G. RNA interference, a potential strategy for isoform-specific phosphatydilinositol 3-kinase targeted therapy in ovarian cancer. Cancer Biol Ther 2004, 3(12), 1283-1289.